KRAS and neoplasm: Chen et al., in a cohort study of 969 KRAS wt mCRC patients treated with third-line cetuximab, demonstrated a significant longer time to treatment discontinuation (p=0.0005) and OS (p <0.0001) in L-sided vs R-sided tumor patients, confirming the prognostic role of primary tumor site (12).